Navigation Links
FDA Provides Guidance for Design of Cell Therapeutics' Pixantrone Pivotal Trial
Date:3/9/2011

SEATTLE, March 10, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) today announced the final clinical trial design of a randomized pivotal trial of pixantrone for the treatment of diffuse large B-cell lymphoma ("DLBCL") following discussions with the  U.S. Food and Drug Administration's (the "FDA") Division of Hematologic Products (the "DHP") .  The new clinical trial, referred to as the PIX-R or PIX 306 trial, will compare a combination of pixantrone plus rituximab to a combination of gemcitabine plus rituximab in patients with relapsed or refractory DLBCL who have received one to three prior lines of therapy, utilizing progression free survival ("PFS") and Overall Survival ("OS")as co-primary endpoints of the study. The PIX-R trial, is targeting to enroll approximately 350 patients over 18 months and will include patients who have failed at least one line of previous therapy and patients who are not candidates for myeloablative chemotherapy and stem cell transplant. During its discussions with the DHP the Company was advised that only OS would be acceptable for a formal Special Protocol Assessment ("SPA") agreement, however the DHP noted that the Company could conduct a study utilizing PFS along with OS as co-primary endpoints which would be an acceptable design outside of the formal SPA process. Regulatory acceptability will depend on the magnitude of the difference between the trial study arms as well as a risk and benefit analysis.

"CTI has worked with the DHP since August on an appropriate clinical trial design that may serve as either a post-marketing commitment trial or as a follow-on pivotal trial depending on the outcome of an appeal of CTI's new drug application for pixantrone based on the PIX 301 trial at the FDA's Office of New Drugs," stated James A. Bianco, M.D., CEO of Cell Therapeutics.

"We believe that pre-clinical data and results from a randomized clinical trial have already demonstrated syn
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Amicus Therapeutics Provides Positive Data Update from Phase 2 Long-Term Extension Study of Amigal™ for Fabry Disease
2. China-Biotics, Inc. Provides Preliminary FY2011Third Quarter Revenue
3. Savient Pharmaceuticals Provides Business Update
4. Celladon Corporation Announces MYDICAR® Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Clinical Improvements in Patients for 12 Months Compared with Placebo
5. Celsion Reports Third Quarter 2010 Financial Results and Provides Business Update
6. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Third Quarter Financial Results
7. Generex Provides Additional Details for October 21st Live Video Webcast
8. Generex Provides Additional Reverse Stock Split Information for the Consideration of Stockholders
9. PDL BioPharma Provides Clarification Regarding Redemption of Its 2.75% Convertible Subordinated Notes
10. PDL BioPharma Provides Third Quarter 2010 Revenue Guidance of Approximately $86 Million and Update to its Correspondence With Genentech
11. NeoStem Provides Second Quarter Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Terascala, the industry leader in ... a former vice president of product management for Flexera ... of marketing. Terascala’s software when combined with leading compute ... highest performance and most reliable solutions for processing big ... channel expansion and broaden its product portfolio. His leadership ...
(Date:7/10/2014)... OMICS Group’s 5th International conference and exhibition ... at Double Tree by Hilton Beijing, China is all ... & Bioanalytical research methods only to facilitate improved living ... Dr. Srinubabu Gedela, MD of OMICS Group Inc has ... one in bringing a unique and international mix of ...
(Date:7/10/2014)... , July 10, 2014  Franciscan ... use of capnography for respiratory monitoring outside ... of healthcare leaders in embracing state-of-the-art patient ... effectively patients are breathing and can alert ... By measuring the amount of carbon dioxide ...
(Date:7/10/2014)... , July 10, 2014 /PRNewswire-iReach/ -- ... and interpretation, today announced an agreement with ... analytics for Lineagen,s NextStep Dx PLUS.  ... neurodevelopmental and neurological disorders, currently offers FirstStep ... (CMA) testing service used by healthcare providers ...
Breaking Biology Technology:Terascala Expands Executive Team 2Terascala Expands Executive Team 3A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4
... BALTIMORE, May 16, 2012  In an effort to voice ... diseases (PIDD), the Immune Deficiency Foundation (IDF) offered oral ... Drug Administration (FDA) public hearing on draft guidance of ... (Ig) therapies from the biosimilars pathways in order to ...
... 12, 2011, nearly fifteen years after she became paralyzed and ... thinking about moving her arm and hand to lift a ... That achievement is one of the advances in brain-computer interfaces ... 17 edition of the journal Nature by the ...
... CENTERVILLE, Mass., May 16, 2012  UV Flu Technologies, ... announce that it has signed a television joint venture ... for the filming of a 60 second commercial, along ... locally, regionally, and nationally, on a variety of television ...
Cached Biology Technology:Immune Deficiency Foundation Urges FDA To Exempt Immunoglobulin From Biosimilars Pathway 2People with paralysis control robotic arms to reach and grasp using brain computer interface 2People with paralysis control robotic arms to reach and grasp using brain computer interface 3People with paralysis control robotic arms to reach and grasp using brain computer interface 4People with paralysis control robotic arms to reach and grasp using brain computer interface 5UV Flu Technologies to Commence a National TV Advertising Campaign 2UV Flu Technologies to Commence a National TV Advertising Campaign 3
(Date:7/10/2014)... July 2, 2014 It is a great ... the appointment of the world-renowned Thoracic and Cardiovascular surgeon, ... Dr. Ginsburg, with over 34 years of ... Hospital and Good Samaritan Regional Medical Center. Dr. Ginsburg ... late 1980,s and is considered an expert in the ...
(Date:7/10/2014)... 3, 2014 Research and Markets ( ... "Global Gesture Recognition & Touch-Less Sensing (2D, ... 2020" report to their offering ... Recognition & Touch-Less Sensing Market to Grow Exponentially. ... while, but the companies were unable to leverage ...
(Date:7/10/2014)... , July 8, 2014 ... won a new design win (DW). An Asian OEM has ... for mass production start in August 2014.   ... smartphone OEM, which has a planned date for start of ... initial ramp order of SEK 5M, for delivery in the ...
Breaking Biology News(10 mins):Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors 2Global Gesture Recognition & Touch-Less Sensing (2D, 3D, Ultrasonic, IR, Capacitive) Market - Forecasts to 2020 2FPC Wins DW and Initial Ramp Order for FPC1021 Touch Sensor for Flagship Smartphone from Asian OEM 2
... children to eat their fruit and vegetables. But once ... often go the way of Barbie dolls and power ... fruits past adolescence. , Fisetin, a naturally occurring flavonoid ... stimulates signaling pathways that enhance long-term memory, report researchers ...
... UT Southwestern Medical Center experts warn that packing on pounds ... Americans who have diabetes and don't even know it. ... a silent killer because its symptoms aren't sudden, but build ... maladies. , That's bad news for those with undiagnosed ...
... archaeon capable of fixing nitrogen at a surprisingly hot ... earliest lineages of organisms capable of nitrogen fixation, perhaps ... animals rely on to fix nitrogen. , The ... Science supports the notion that the gene needed to ...
Cached Biology News:A natural chemical found in strawberries boosts memory in healthy mice 2A natural chemical found in strawberries boosts memory in healthy mice 3Holiday gluttony can spell disaster for undiagnosed diabetics 2Microbe fixes nitrogen at a blistering 92 C 2Microbe fixes nitrogen at a blistering 92 C 3
Immunogen: Human Respiratory Syncytial Virus (RSV) and Bovine Respiratory Syncytial Virus (BRSV) Fusion protein Storage: -20 C, Avoid Freeze/Thaw Cycles...
The DNA DipStick Kit is ideal for estimating nucleic acid concentrations and approximate yields. Works with ss- and ds-DNA, RNA, and oligonucleotides at concentrations as low as 0.1 ng/l....
Tris-Hepes kit of BG-163 & BG-165 (order number BG-166)...
... Immunogen: Synthetic peptide derived from the ... protein. Specificity: Reacts with the ... Reactivity: Human Mouse (positive controls: WNT1-transfected ... lysates and mouse Mouse-1 cell lysates). ...
Biology Products: